Chris Dobson, Master of Protein Folding Research, Dies at 69
A chemist at the University of Cambridge, Dobson developed equations that described the kinetics of protein aggregation in diseases such as Alzheimer’s.
6401 RESULTS
Sort By:
A chemist at the University of Cambridge, Dobson developed equations that described the kinetics of protein aggregation in diseases such as Alzheimer’s.
By Jennifer Altman, based on her original report in Alzheimer Actualités, a newsletter published by the <a href="http://www.ipsen.com/homeFondation.jsp" target="_new">Ipsen Foundation</a>...
The organizers of this year's special interest social on Alzheimer's disease decided to stage an awards ceremony to salute scientists who had distinguished themselves in various categories not ordinarily recognized...
It has been a century since Alzheimer and Bielchowsky reported senile plaques (SP) in AD brain, but it was only relatively recently appreciated that SPs are embraced by reactive astrocytes and microglia...
Last July, Dale Schenk and colleagues from Elan Pharmaceuticals reported the remarkable observation that simple immunization of PDAPP transgenic mice...
Tomlinson was the first to quantify plaques and tangles in the postmortem brain, launching the modern era of Alzheimer’s research.
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
Alector’s AL002c antibody mobilizes microglia, reduces neuronal dystrophy, and restores normal behavior—all in mice. The clinical version is in Phase 1.
Removing cataracts cuts a person's risk of dementia. Cochlear implants stall mild cognitive impairment. Could treating sensory losses hold some dementia cases at bay?
In some people who had weathered COVID at home, olfactory regions in the brain shrank and executive function slowed. Will these changes resolve or persist?
To find true brain-behavior correlations, a brain-wide association study needs orders of magnitude more people than the dozens typically used in neuroimaging research.
Taking a stab at secondary prevention, the four-year Phase 3 trial will assess the antibody’s ability to slow slippage in 1,200 cognitively healthy, amyloid-positive people.
Synapses go haywire long before people with Alzheimer’s disease suspect problems with their memory, but what primes neurons for synaptic dysfunction in the first place?...
A new tracer detects α-synuclein aggregates in people with multiple system atrophy. Binding is weak, and undetectable in people with other synucleinopathies.
Patients taken off the drug continue to outperform those who were never on it, and decline slows even more once treatment resumes. Cognition and plasma Aβ changes are consistent with disease-modifying effect.